TABLE 2.

Primers used in this study

Primer	Sequence
Degenerate primers
N terminal	5′ GCNCCNACNCARGGNGAYGGNACN 3′
C terminal	5′ NARRTARTTNARNGTRAARTTNGC 3′
Adapter sequence	5′ GATCCTAATACCACTCACATAGGGCGGCCGCCCGGGC 3′, 3′ GATTATGGTGAGTGTATCCCGCCGGCGGGCCCG 5′
WP1	5′ GATCCTAATACCACTCACATAGGGCGGCCGCCCGGGC 3′
Biotinylated primer (BP1)	5′ GTGTTCAGGTTTTGATTCACCACCATC 3′
IP2	5′ GTTCTTGATTGAACAGGCTGC 3′
Primers for amplifying 537-bp fragment
Forward primer	5′ GGATCCATGAAACTTAACACAATTGGC 3′
Reverse primer	5′ AAGCTTAAGGTAGTTGAGAGTGAAGTTG 3′
Primers for point mutations
Val32Ala (forward)	5′ CTCAAGGTGACGGCGCAGCAAAATTCACCGGTTCTATTATTAATG 3′
Phe34Ala (forward)	5′ GGTGACGGCGCAGTTAAAGCAACCGGTTCTATTATTAATGC 3′
Ile38Ala (forward)	5′ GCAGTTAAATTCACCGGTTCTGCAATTAATGCAGCCTGTTCAATC 3′
Triple mutation (forward)	5′ CTCAAGGTGACGGCGCGCAAAGCAACCGGTTCGCAATTAATGCAGCCTGTTCAAT
(Val-Phe-Ile→Ala-Ala-Ala)	CAAG 3′